

*Preliminary Amendment
USSN 09/851,614
Attorney Docket No. MXI-166
Page 7 of 8*

REMARKS

Claims 1-55 were pending in the application and have been cancelled herein. New claims 56-78 have been added. Accordingly, after the amendments presented herein have been entered, claims 56-78 will be pending. Support for claims 56-78 can be found throughout the specification and in the claims as originally filed. No new matter has been added.

In particular, claim 56 is drawn to human antibodies which have particular properties. Support for these properties can be found, for example, at pages 56 and 57 (property (a)), page 58, lines 10-26 (property (b)), page 64, line 28 to page 65, line 5 (property (c)), page 65, line 11 to page 66, line 18 (property (d)) and page 66, line 23 to page 67, line 27 (property (e)), of the present specification. Support for claim 57 can be found at, for example, page 59, line 28 through page 61. Support for claim 58 can be found at, for example, page 63, line 9 to page 64, line 25. Support for claim 59 can be found at, for example, page 64, lines 23-25. Support for claims 60 and 61 can be found at, for example, page 14, lines 3-8. Support for claim 62 can be found at, for example, page 14, lines 13-14. Support for claim 63 can be found at, for example, page 10, line 20 to page 11, line 19. Support for claims 64-70 can be found in the specification at those locations set forth above for claim 56, the Sequence Listing and Figure 13. The CDR1, CDR2 and CDR3 amino acid sequences set forth in new claims 64-66 and 69 are present within the light and heavy chain variable region sequences (SEQ ID NOs: 2 and 4, respectively) of human antibody B11, as exemplified in the specification, and were identified using standard CDR mapping techniques well known to those of ordinary skill in the art. Accordingly, the CDRs delineated in new claims 64-66 and 69 are an inherent feature, recognizable by one of ordinary skill in the art, of the complete variable region sequences of antibody B11, as originally filed in the present application. Furthermore, the human germline sequences from which B11 arises, as set forth in new claim 70, were identified using standard germline comparison techniques well known to those of

*Preliminary Amendment
USSN 09/851,614
Attorney Docket No. MXI-166
Page 8 of 8*

ordinary skill in the art. Accordingly, the germline sequences set forth in new claim 70 are an inherent feature, recognizable by one of ordinary skill in the art, of the complete variable region sequences of antibody B11, as originally filed in the present application. As such, new claims 64-66, 69 and 70 are fully supported by the present specification and do not add new matter. Support for new claims 71 and 76 can be found in the specification at, for example, pages 38-45. Support for new claims 72-75, 77 and 78 can be found in the specification at, for example, 47, lines 5-25.

CONCLUSION

It is respectfully submitted that this application is in condition for allowance. If there are any remaining issues, or the Examiner believes that a telephone conversation with Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP


Jane E. Remillard, Esq.
Reg. No. 38,872

Attorney for Applicants

Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109
Telephone: (617) 227-7400
Facsimile: (617) 742-4214

Date: October 7, 2003

RECEIVED
CENTRAL FAX CENTER

OCT 08 2003

OFFICIAL